Core Insights - NextCure, Inc. has initiated the first patient dosing in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate aimed at treating multiple cancers [1][2] - The company views this milestone as significant for advancing its B7-H4 ADC program and aims to establish the safety, tolerability, and preliminary anti-tumor activity of LNCB74 [2] - The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug application for LNCB74 in December 2024, facilitating the commencement of this clinical trial [2] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies for patients who do not respond to existing treatments [3] - The company employs differentiated mechanisms of action, including antibody-drug conjugates, antibodies, and proteins, to advance its therapeutic offerings [3] - NextCure collaborates with LigaChem Biosciences, Inc. for the development of LNCB74 under a co-development agreement [3]
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers